Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Completed

Phase 2 Results N/A

Summary of Purpose

The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stroke or TIA.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 26 April 2017.

25 Apr 2016 29 Jan 2016 31 Mar 2017 31 Mar 2017 1 Apr 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:

    Clinical.Trials@bms.com

  • First line of the email MUST contain NCT# and Site #.